Patient groups urge Congress to reauthorize Prescription Drug User Fee Act, improve clinical trial diversity

Senate passes stopgap bill that would ban OMB from finalizing rule that would politicize science

The U.S. Senate has passed a stopgap spending bill that, in addition to avoiding a government shutdown at the end of September, would preclude the White House Office of Management and Budget from finalizing a proposal that seeks to fundamentally redraw the ground rules for all federally funded research (The Cancer Letter, Aug. 7, 2026).

SANRECO phase II study of divesiran in polycythemia vera meets primary endpoint

The SANRECO phase II trial of divesiran, a first-in-class siRNA, in 48 phlebotomy-dependent patients with polycythemia vera, met its primary endpoint and secondary endpoints. The 36-week, randomized, double-blind, placebo-controlled portion of the trial administered divesiran subcutaneously (6 mg/kg) every six weeks or every twelve weeks.

August 14, 2026

Vol.52 No.32

Cancer Policy

HRSA redrafts 340B rebate pilot program after courts block the original version

After returning to the drawing board, the Health Resources and Services Administration has announced a second iteration of the 340B Rebate Model Pilot Program, after it withdrew the original pilot earlier this year.

Phase III XPORT-EC-042 trial in endometrial cancer does not meet primary endpoint

The phase III XPORT-EC-042 trial, evaluating selinexor as a maintenance-only therapy compared to placebo in adult patients with TP53 wild-type advanced or recurrent endometrial cancer, did not meet its primary endpoint of progression free survival.

August 07, 2026

Vol.52 No.31

Clinical Roundup

How to boost enrollment of Black and Hispanic patients in pediatric clinical trials

While Black and Hispanic families are enthusiastic about research participation, other provider- and systems-focused factors may influence their involvement in pediatric oncology clinical trials, according to a study led by researchers at UT Southwestern Medical Center and Dana-Farber/Mass General.

August 07, 2026

Vol.52 No.31

Podcast

Pour a Scotch, we’re talking clinical trials and prediction markets

In last week’s issue of The Cancer Letter, the cover story featured coverage of Kalshi, an online prediction market exchange, launching a pilot program in which one can place bets on both outcomes of trials and FDA decisions.

August 05, 2026

Vol.52 No.31

Patient groups urge Congress to reauthorize Prescription Drug User Fee Act, improve clinical trial diversity

YOU MAY BE INTERESTED IN

Senate passes stopgap bill that would ban OMB from finalizing rule that would politicize science

SANRECO phase II study of divesiran in polycythemia vera meets primary endpoint

HRSA redrafts 340B rebate pilot program after courts block the original version

Phase III XPORT-EC-042 trial in endometrial cancer does not meet primary endpoint

How to boost enrollment of Black and Hispanic patients in pediatric clinical trials

Pour a Scotch, we’re talking clinical trials and prediction markets

Renew today!

Subscriber content

Never miss an issue!

Login